Ann: CEO Presentation to 2021 Annual General Meeting, page-51

Focus

The company is focused on Remestemcel-l for Covid-19 Ards EUA with Novartis as the blockbuster.

Approval of Remestemcel-l potency assays at OTAT
allows for the resubmission of BLA for paediatric AGvHD.


Approval of Ryoncil on the paediatric market is one step -

Everything else is noise.

My guess - my noise if you like

Confirmatory Covid-19 Ards trial will commence in partnership with Novartis immediately on OTAT concurring with the FDA that the potency assays are
acceptable.

By the time - 6 months- the BLA has gone through the process it’s feasible that a trial conducted in under 65s
with elevated Crp levels will have been stopped for
overwhelming efficacy.


FDA then grants the EUA for COVID-19


Who’s is going to stop a cure?

Unmet need people .


Unmet need for Severe Ards -


Mass production is the missing link for an EUA- ahhh welcome back to the circle of life- that’s why Novartis
is waiting. Size of partnership will depend on what needs
to be invested to scale and the supply limitations will affect
market valuations.


We ain’t trying to develop a cold and flu tablet


It’s a tad more important

Rant over


Sorry



Reg